Jaktinib Hydrochloride for the Treatment of Ruxolitinib Intolerance of Myelofibrosis
Status:
Recruiting
Trial end date:
2022-09-18
Target enrollment:
Participant gender:
Summary
This phase IIB, open-label, multicenter study evaluated the efficacy and safety of oral
Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis and
Previously Treated With Ruxolitinib. The experiment is divided into two parts: dose
exploration and extended research.